MET D1228N

CI-VAR-00000412Explore in graph →NP_000236.2:p.Asp1228AsnNM_000245.4:c.3682G>AClinVar 13884 CIViC 649 rs121913671

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Adenocarcinoma1
MET Exon 14 Skipping Mutation AND MET D1228N	Crizotinib	Predictive	C	Supports Resistance	2	submitted	EID11413 A 70-year old male (former smoker: 50 pack-years) was diagnosed with stage Ib lung adenocarcinoma. Next-generation sequencing showed a MET exon 14 skipping mutation, confirmed later with RNA analysis.… (full text at CIViC) PMID 34994615 · Pruis et al., 2021 · Open in CIViC	civic
Lung Non-Small Cell Carcinoma2
MET D1228N	Crizotinib	Predictive	C	Supports Resistance	2	accepted	EID1652 Case report of a patient with NSCLC harboring a MET exon 14 skipping mutation and initial response to crizotinib. A second biopsy at the time of progression revealed an acquired MET D1228N mutation. PMID 27343442 ·

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
13884	Uncertain significance	criteria provided, single submitter	1	Papillary renal cell carcinoma type 1; Embryonal rhabdomyosarcoma; Hereditary cancer-predisposing syndrome	germline/somatic	3	Apr 10, 2026	clinvar